2002

Mar 11, 2002
First European Patient Treated With Guidant's Next-Generation Beating-Heart Surgery Product

New Stabilizer Systems Designed to Make Procedure Available to More Patients Brussels, Belgium and Mainz, Germany - Guidant Corporation (NYSE and PCX: GDT), a world leader in the treatment of...

Mar 7, 2002
Guidant Halts Further Development on Actinomycin-D Drug Eluting Stent Program

Company to Host Webcast/Conference Call Today Indianapolis, IN - Guidant Corporation (NYSE and PCX: GDT), a global leader in cardiac and vascular technology, today reported preliminary results of...

Mar 4, 2002
Guidant Completes Enrollment Of Paclitaxel Drug-Eluting Stent U.S. Trial

Clinical Trial Fully Enrolled In Less Than Four Months Indianapolis, IN - Guidant Corporation (NYSE and PCX: GDT), a global leader in cardiac and vascular technology, today announced that it has...

Feb 27, 2002
Guidant Announces CE Mark Approval of Next Generation Lead for Use with Heart Failure Devices

Innovative Lead Instrumental in Delivering Therapy for Heart Failure Patients Indianapolis, IN - Guidant Corporation (NYSE and PCX: GDT), a world leader in the treatment of cardiovascular and...

Feb 22, 2002
Guidant Comments on the Status of its ACTION Drug Eluting Stent Trial

Indianapolis, Ind. - Guidant Corporation (NYSE and PCX: GDT), a global leader in cardiac and vascular technology, today issued the following statement on the status of its international ACTION...

Show 5102550100 per page
Top